­
­
­
­

Inventi Impact - Pharmacy Practice

Articles

  • Inventi:ppp/27341/18
    CLINICAL EFFECTS OF METFORMIN THERAPY ON HYPERANDROGENISM AND ANOVULATION IN NON-OBESE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME
    Naila Zahid, Hammad Ahmed, Muhammad Aslam*

    Polycystic ovary syndrome is an ovarian disorder producing multiple cysts filled with serous fluid that produces excess number of androgens dominantly testosterone and estrogens. Polycystic ovarian syndrome (PCOS) women are associated with hyperandrogenism, oligomenorrhea, infertility, hirsutism, hyperinsulinaemia (type 2 diabetes) and rarely virilism. In our study, a total of 83 patients were selected that were diagnosed with PCOS, out of which 47 (56.63%) were in the age group of 15-25 years. 61 (73.49%) respondents were receiving metformin for the period of 1-6 months whereas 26 (31.33%) respondents received the same drug for the time period of 7-12 months. The duration of treatment strictly based on the age factor and life of the disorder. Patients fall in the age group of 15-25 years have abnormal number of follicles 28 (32.53%) and 19 (22.89%) respondents have abnormal number of follicles having age in between of 26-35. Metformin is not an effective first line treatment in non-obese women with polycystic ovarian syndrome. Among 83 non-obese and non-diabetic women only 27 women got benefit but no ovulation occurred from metformin therapy while other 57 women did not get any beneficial clinical effect. It is, therefore, concluded from the result that metformin should only be referred as first line therapy or synergistic agent in obese women who have hyperinsulinaemia but not in non-insulin resistant patients.

    How to Cite this Article
    Naila Zahid, Hammad Ahmed, Muhammad Aslam. Clinical Effects of Metformin Therapy on Hyperandrogenism and Anovulation in Non-Obese Women with Polycystic Ovarian Syndrome. Inventi Impact: Pharmacy Practice, 2019(2):66-69, 2019.
    Download Full Text